Trogarzo (Ibalizumab-uiyk) for Multidrug Resistant HIV-1March 8, 2018
Trogarzo (Ibalizumab-uiyk, formerly TMB-355) is a first-in-class viral entry inhibitor that targets a human protein rather than attacking HIV directly. It binds to extracellular domain 2 of CD4 receptors, thereby blocking entry of HIV into CD4 lymphocytes. Because of its unique mechanism of action, Trogarzo is indicated for use in heavily treatment-experienced patients infected with highly resistant HIV who have limited remaining treatment options. Trogarzo is administered via intravenous (IV) infusion every 2 weeks, in combination with an optimized background antiretroviral therapy (ART) regimen that includes at least 1 active antiretroviral agent.
If you have a Hayes login, click here to view the full report on the Knowledge Center.